Robust, Futureproof, IP Protection in Biotech

Your IP is one of your company’s most valuable assets—and the way you protect it should reflect that. Read on to explore how ZONTAL has helped leading pharma and biotech companies achieve IP security.

In the past, scientists used paper notebooks written in ink. Today, electronic lab notebooks (ELN) are the standard. However, most ELNs do not offer the ability to create digital signatures for their records. It’s also common for large biotechs to use multiple different ELN systems. Without additional safeguards, ELN entries may not provide the necessary evidence in court.

By implementing ZONTAL, leading biotech companies save time and money while protecting their reputation and maintaining regulatory compliance.